Metformin use and long-term risk of benign prostatic hyperplasia: a population-based cohort study.

ABSTRACT:

Objective

To assess whether metformin use affects risk of benign prostatic hyperplasia (BPH) by comparing the risk of BPH in men with type 2 diabetes who initiated first-line treatment with either metformin or sulfonylurea monotherapy between 2000 or 2006 in Northern Denmark. In this period, sulfonylurea and metformin were both frequently used as first-line glucose-lowering drug (GLD) treatment.

Design

A population-based cohort study.

Setting

Northern Denmark.

Participants

All men who filled at least two prescriptions for metformin or for sulfonylurea, respectively, during their first 6 months of GLD treatment. Follow-up started 6 months after treatment start.

Primary outcome measures

Rates of subsequent BPH, identified based on community prescriptions f

SUBMITTER: Norgaard M 

PROVIDER: S-EPMC7757457 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature